Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 3Terminated 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Gastrointestinal 1

Conditions

Breast Neoplasms 15Stomach Neoplasms 6Neoplasms 2Inflammatory Breast Neoplasms 2Esophageal Neoplasms 2pCR Rate 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Testicular Germ Cell Tumor 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Oesophago-gastric Cancer 1Neoplasms, Germ Cell and Embryonal 1Nasopharyngeal Carcinoma 1Epstein-Barr Virus Infections 1Cardiotoxicity 1Breast Neoplasms, Male 1

Interventions

Gemcitabine 34pembrolizumab 26Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Neoplasms × Epirubicin × Clear all
NCT00954512 2018-08-24

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Merck Sharp & Dohme LLC

Phase 1/2 Terminated
15 enrolled 11 charts
Tumor-Agnostic

Neoplasms

NCT00130936 2016-02-15

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

AHS Cancer Control Alberta

Phase 1/2 Terminated
50 enrolled
Gastrointestinal

Esophageal Neoplasms, Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡